Review Article | Published:

Polycystic ovary syndrome: etiology, pathogenesis and diagnosis

Nature Reviews Endocrinology volume 7, pages 219231 (2011) | Download Citation

This article has been updated

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age, with a prevalence of up to 10%. Various diagnostic criteria have been proposed, generally centered around the features of hyperandrogenism and/or hyperandrogenemia, oligo-ovulation and polycystic ovarian morphology. Insulin resistance is present in a majority of cases, with compensatory hyperinsulinemia contributing to hyperandrogenism via stimulation of ovarian androgen secretion and inhibition of hepatic sex hormone-binding globulin production. Adipose tissue dysfunction has been implicated as a contributor to the insulin resistance observed in PCOS. Environmental and genetic factors also have a role in the development of PCOS. The syndrome is associated with numerous morbidities, including infertility, obstetrical complications, type 2 diabetes mellitus, cardiovascular disease, and mood and eating disorders. Despite these morbidities, PCOS may be common in our society owing to evolutionary advantages of the syndrome in ancient times, including smaller family sizes, reduced exposure to childbirth-related mortality, increased muscle mass and greater capacity to store energy. The diagnosis of PCOS hinges on establishing key features while ruling out other hyperandrogenic or oligo-ovulatory disorders. Treatment is focused on the goals of ameliorating hyperandrogenic symptoms, inducing ovulation and preventing cardiometabolic complications.

Key points

  • The central diagnostic features of polycystic ovary syndrome (PCOS) are hyperandrogenemia, hyperandrogenism (hirsutism), oligoanovulation and polycystic ovaries; the three main diagnostic schemes utilize different combinations of these criteria

  • The prevalence of PCOS in women of reproductive age is 6–10%; prevalence is remarkably similar across different populations across the globe

  • Insulin resistance, a common feature of PCOS that arises in part from adipose tissue dysfunction, results in compensatory hyperinsulinemia, which maintains normal glucose levels but adversely effects ovarian androgen production

  • Abnormal folliculogenesis and gonadotropin production, particularly luteinizing hormone hypersecretion, also contribute to the development of PCOS; these abnormalities may arise from environmental insults as well as genetic predisposition

  • Long-term complications of PCOS include infertility, obstetrical complications, type 2 diabetes mellitus, cardiovascular disease, and mood and eating disorders

  • Treatment of PCOS must be tailored to the specific needs of each patient; goals of therapy may include ameliorating hyperandrogenic symptoms, inducing ovulation, regulating menstruation and preventing cardiometabolic complications

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 10 February 2011

    In the version of this article initially published online, there was a mistake in the Hirsutism section on page 7. In the first paragraph of this section, the phrase "flutamide 2.5–5 mg per day" should have read "flutamide 62.5–250 mg per day". The error has been corrected in all electronic versions of the text.

References

  1. 1.

    in Androgen Excess Disorders in Women 2nd edn (eds Azziz, R., Nestler, J. E. & Dewailly, D.) 1–16 (Humana Press, Totowa, 2006).

  2. 2.

    & Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181–191 (1935).

  3. 3.

    & in Polycystic Ovary Syndrome (eds Dunaif, A., Givens, J. R., Haseltine, F. P. & Merriam G. R.) 377–384 (Blackwell Scientific, Boston, 1992).

  4. 4.

    [No authors listed] Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81, 19–25 (2004).

  5. 5.

    [No authors listed] Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41–47 (2004).

  6. 6.

    et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91, 4237–4245 (2006).

  7. 7.

    et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 85, 2434–2438 (2000).

  8. 8.

    et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89, 2745–2749 (2004).

  9. 9.

    et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84, 4006–4011 (1999).

  10. 10.

    et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J. Clin. Endocrinol. Metab. 83, 3078–3082 (1998).

  11. 11.

    , , & Polycystic ovaries and associated clinical and biochemical features in young women. Clin. Endocrinol. (Oxf.) 51, 779–786 (1999).

  12. 12.

    et al. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 113, 1210–1217 (2006).

  13. 13.

    et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009).

  14. 14.

    et al. Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab. 89, 453–462 (2004).

  15. 15.

    et al. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin. Endocrinol. (Oxf.) 37, 127–134 (1992).

  16. 16.

    & Ultrasound diagnosis of polycystic ovaries in women who have no symptoms of polycystic ovary syndrome is not associated with subfecundity or subfertility. Fertil. Steril. 80, 966–975 (2003).

  17. 17.

    , , , & Isolated polycystic morphology in ovum donors predicts response to ovarian stimulation. Hum. Reprod. 10, 524–528 (1995).

  18. 18.

    , , , & Visually scoring hirsutism. Hum. Reprod. Update 16, 51–64 (2010).

  19. 19.

    , , , & Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J. Clin. Endocrinol. Metab. 92, 405–413 (2007).

  20. 20.

    , & Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil. Steril. 93, 1938–1941 (2010).

  21. 21.

    Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol. Endocrinol. 1, 235–245 (1987).

  22. 22.

    et al. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum. Reprod. 18, 598–603 (2003).

  23. 23.

    Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr. Rev. 17, 121–155 (1996).

  24. 24.

    , , & Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol. Hum. Reprod. 4, 1–8 (1998).

  25. 25.

    , & A mechanism for the suppression of estrogen production in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81, 3686–3691 (1996).

  26. 26.

    , & 5alpha-reductase activity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 84, 2414–2418 (1999).

  27. 27.

    et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab. 85, 139–146 (2000).

  28. 28.

    , , , & Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil. Steril. 59, 323–331 (1993).

  29. 29.

    , , & Polycystic Ovary Syndrome. A Guide to Clinical Management (Taylor & Francis, London, 2005).

  30. 30.

    , , & Insulin action in the normal and polycystic ovary. Endocrinol. Metab. Clin. North Am. 28, 361–378 (1999).

  31. 31.

    , , & Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J. Clin. Endocrinol. Metab. 81, 302–309 (1996).

  32. 32.

    & Local roles of TGF-beta superfamily members in the control of ovarian follicle development. Anim. Reprod. Sci. 78, 165–183 (2003).

  33. 33.

    & Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertil. Steril. 88, 539–546 (2007).

  34. 34.

    , , & Anti-Müllerian hormone: a new marker for ovarian function. Reproduction 131, 1–9 (2006).

  35. 35.

    et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J. Clin. Endocrinol. Metab. 92, 240–245 (2007).

  36. 36.

    , , , & Granulosa cells of polycystic ovaries: are they normal or abnormal? Hum. Reprod. 7, 293–299 (1992).

  37. 37.

    et al. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. J. Clin. Endocrinol. Metab. 79, 1355–1360 (1994).

  38. 38.

    , & Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 83, 1454–1460 (2005).

  39. 39.

    , , & Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84, 165–169 (1999).

  40. 40.

    , , , & Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 66–71 (2005).

  41. 41.

    et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J. Clin. Invest. 96, 520–527 (1995).

  42. 42.

    , , & Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89, 1273–1276 (2004).

  43. 43.

    , & Impact of obesity on the risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 162–168 (2008).

  44. 44.

    et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J. Clin. Endocrinol. Metab. 92, 2500–2505 (2007).

  45. 45.

    et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 75, 577–583 (1992).

  46. 46.

    , , & Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am. J. Physiol. Endocrinol. Metab. 281, E392–E399 (2001).

  47. 47.

    , , , & Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J. Clin. Endocrinol. Metab. 94, 157–163 (2009).

  48. 48.

    , & Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am. J. Physiol. 264, E197–E202 (1993).

  49. 49.

    Molecular defects of insulin action in the polycystic ovary syndrome: possible tissue specificity. J. Pediatr. Endocrinol. Metab. 13 (Suppl. 5), 1291–1293 (2000).

  50. 50.

    et al. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J. Clin. Endocrinol. Metab. 82, 1421–1425 (1997).

  51. 51.

    et al. Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. J. Clin. Endocrinol. Metab. 93, 3618–3626 (2008).

  52. 52.

    et al. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes 57, 357–366 (2008).

  53. 53.

    et al. Low body adiposity and high leptinemia in breast-fed infants born small-for-gestational-age. J. Pediatr. 156, 145–147 (2010).

  54. 54.

    & It's not how fat you are, it's what you do with it that counts. PLoS Biol. 6, e237 (2008).

  55. 55.

    & Adipose tissue expandability, lipotoxicity and the metabolic syndrome—an allostatic perspective. Biochim. Biophys. Acta 1801, 338–349 (2010).

  56. 56.

    et al. Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-{alpha}. J. Clin. Endocrinol. Metab. 95, 935–942 (2010).

  57. 57.

    in Infertility, Contraception, and Reproductive Endocrinology 3rd edn (eds Mishell, D. R. Jr, Davajan, V. & Lobo, R. A.) 447–487 (Blackwell Scientific Publications, Cambridge, 1991).

  58. 58.

    , & The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum. Reprod. Update 12, 351–361 (2006).

  59. 59.

    , & Regulation of gonadotropin secretion: implications for polycystic ovary syndrome. Semin. Reprod. Med. 20, 317–326 (2002).

  60. 60.

    , , , & Hyperfunction of the hypothalamic–pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J. Clin. Endocrinol. Metab. 66, 165–172 (1988).

  61. 61.

    et al. Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. J. Clin. Endocrinol. Metab. 90, 2810–2815 (2005).

  62. 62.

    & Neuroendocrine aspects of polycystic ovary syndrome. Endocrinol. Metab. Clin. North Am. 28, 295–324 (1999).

  63. 63.

    et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J. Clin. Endocrinol. Metab. 85, 4047–4052 (2000).

  64. 64.

    et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J. Clin. Endocrinol. Metab. 79, 1328–1333 (1994).

  65. 65.

    , , & Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertil. Steril. 53, 785–791 (1990).

  66. 66.

    et al. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J. Clin. Endocrinol. Metab. 91, 1309–1316 (2006).

  67. 67.

    et al. Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 92, 1347–1352 (2007).

  68. 68.

    , , & Insights into hypothalamic–pituitary dysfunction in polycystic ovary syndrome. J. Endocrinol. Invest. 21, 602–611 (1998).

  69. 69.

    et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82, 2248–2256 (1997).

  70. 70.

    , , & Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum. Reprod. Update 11, 357–374 (2005).

  71. 71.

    , & Polycystic ovary syndrome and its developmental origins. Rev. Endocr. Metab. Disord. 8, 127–141 (2007).

  72. 72.

    et al. Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys. Biol. Reprod. 79, 154–163 (2008).

  73. 73.

    , & Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am. J. Primatol. 71, 776–784 (2009).

  74. 74.

    , , & Prenatal testosterone excess programs reproductive and metabolic dysfunction in the female. Mol. Cell. Endocrinol. 246, 165–174 (2006).

  75. 75.

    , , & in Novel Concepts in Ovarian Endocrinology (ed. Gonzalez-Bulnez, A.) 329–352 (Transworld Research Network, Kerala, 2007).

  76. 76.

    , & Early origins of polycystic ovary syndrome. Reprod. Fertil. Dev. 17, 349–360 (2005).

  77. 77.

    et al. The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. J. Clin. Endocrinol. Metab. 94, 3714–3720 (2009).

  78. 78.

    & Early origins of polycystic ovary syndrome: hypotheses may change without notice. J. Clin. Endocrinol. Metab. 94, 3682–3685 (2009).

  79. 79.

    et al. Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. J. Clin. Endocrinol. Metab. 95, 2180–2186 (2010).

  80. 80.

    et al. Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J. Obstet. Gynaecol. 30, 444–446 (2010).

  81. 81.

    et al. Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 2739–2743 (2007).

  82. 82.

    et al. Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 3105–3109 (2006).

  83. 83.

    et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 94, 1923–1930 (2009).

  84. 84.

    et al. Circulating maternal testosterone concentrations at 18 weeks of gestation predict circulating levels of antimüllerian hormone in adolescence: a prospective cohort study. Fertil. Steril. 94, 1544–1547 (2010).

  85. 85.

    et al. Metabolic parameters in cord blood of newborns of women with polycystic ovary syndrome. Fertil. Steril. 92, 277–282 (2009).

  86. 86.

    , , & Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J. Clin. Endocrinol. Metab. 83, 3558–3562 (1998).

  87. 87.

    Clinical review: Identifying children at risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 787–796 (2007).

  88. 88.

    et al. Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 94, 3282–3288 (2009).

  89. 89.

    Polycystic ovary syndrome in adolescents. Int. J. Obes. (Lond.) 32, 1035–1041 (2008).

  90. 90.

    et al. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J. Clin. Endocrinol. Metab. 92, 430–436 (2007).

  91. 91.

    & The inheritance of polycystic ovarian disease and a possible relationship to premature balding. Clin. Endocrinol. (Oxf.) 11, 291–300 (1979).

  92. 92.

    , , , & Familial polycystic ovaries: a genetic disease? Clin. Endocrinol. (Oxf.) 29, 593–605 (1988).

  93. 93.

    , , , & Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil. Steril. 75, 53–58 (2001).

  94. 94.

    , , , & Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc. Natl Acad. Sci. USA 95, 14956–14960 (1998).

  95. 95.

    , , & Familial clustering in the polycystic ovarian syndrome. Gynecol. Obstet. Invest. 28, 23–30 (1989).

  96. 96.

    et al. Hyperthecosis: an inheritable form of polycystic ovarian disease. Birth Defects Orig. Artic. Ser. 11, 81–85 (1975).

  97. 97.

    , , & Heritability of polycystic ovary syndrome in a Dutch twin-family study. J. Clin. Endocrinol. Metab. 91, 2100–2104 (2006).

  98. 98.

    , & Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J. Clin. Endocrinol. Metab. 86, 2027–2031 (2001).

  99. 99.

    et al. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87, 2134–2138 (2002).

  100. 100.

    , , , & Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries. Clin. Endocrinol. (Oxf.) 60, 322–328 (2004).

  101. 101.

    , , & High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity. J. Clin. Endocrinol. Metab. 94, 4361–4366 (2009).

  102. 102.

    Looking for polycystic ovary syndrome genes: rational and best strategy. Semin. Reprod. Med. 26, 5–13 (2008).

  103. 103.

    et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J. Clin. Endocrinol. Metab. 89, 2408–2413 (2004).

  104. 104.

    et al. Nonreplication of the type 5 17beta-hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 300–303 (2008).

  105. 105.

    et al. Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J. Clin. Endocrinol. Metab. 90, 2988–2993 (2005).

  106. 106.

    et al. Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J. Clin. Endocrinol. Metab. 90, 6623–6629 (2005).

  107. 107.

    et al. Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17beta-hydroxysteroid dehydrogenase gene. J. Clin. Endocrinol. Metab. 94, 5034–5038 (2009).

  108. 108.

    et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95, 2306–2315 (2010).

  109. 109.

    & Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nat. Clin. Pract. Endocrinol. Metab. 4, 156–163 (2008).

  110. 110.

    et al. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil. Steril. 91 (Suppl.), 1332–1335 (2009).

  111. 111.

    , , , & Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J. Clin. Endocrinol. Metab. 90, 2545–2549 (2005).

  112. 112.

    , , , & Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J. Clin. Endocrinol. Metab. 91, 3922–3927 (2006).

  113. 113.

    & Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum. Reprod. Update 15, 477–488 (2009).

  114. 114.

    et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum. Reprod. 24, 2286–2292 (2009).

  115. 115.

    et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J. Clin. Endocrinol. Metab. 91, 4842–4848 (2006).

  116. 116.

    , , , & Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum. Reprod. 18, 2289–2293 (2003).

  117. 117.

    , , , & Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum. Reprod. 13, 1502–1505 (1998).

  118. 118.

    , , , & Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil. Steril. 61, 598–604 (1994).

  119. 119.

    , & Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J. Clin. Endocrinol. Metab. 84, 1470–1474 (1999).

  120. 120.

    et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J. Clin. Endocrinol. Metab. 68, 173–179 (1989).

  121. 121.

    , , , & Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil. Steril. 92, 1966–1982 (2009).

  122. 122.

    , & Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl. Physiol. Nutr. Metab. 31, 384–391 (2006).

  123. 123.

    , , , & Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr. Rev. 30, 75–95 (2009).

  124. 124.

    , , , & Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells. Mol. Cell. Endocrinol. 283, 12–18 (2008).

  125. 125.

    , , , & The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance. Environ. Health Perspect. 114, 106–112 (2006).

  126. 126.

    , , , & Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr. J. 51, 165–169 (2004).

  127. 127.

    et al. Gender difference in serum bisphenol A levels may be caused by liver UDP-glucuronosyltransferase activity in rats. Biochem. Biophys. Res. Commun. 325, 549–554 (2004).

  128. 128.

    et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr. Rev. 30, 293–342 (2009).

  129. 129.

    [No authors listed] Consensus on infertility treatment related to polycystic ovary syndrome. Fertil. Steril. 89, 505–522 (2008).

  130. 130.

    & A macaque model for studying mechanisms controlling oocyte development and maturation in human and non-human primates. Hum. Reprod. 14, 2544–2555 (1999).

  131. 131.

    et al. Normal development and metabolic activity of preimplantation embryos in vitro from patients with polycystic ovaries. Hum. Reprod. 10, 2125–2135 (1995).

  132. 132.

    et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum. Reprod. Update 12, 13–21 (2006).

  133. 133.

    et al. The outcome of in vitro fertilization and embryo transfer in women with polycystic ovary syndrome failing to conceive after ovulation induction with exogenous gonadotropins. Fertil. Steril. 57, 1269–1273 (1992).

  134. 134.

    et al. IVF versus ICSI in sibling oocytes from patients with polycystic ovarian syndrome: a randomized controlled trial. Hum. Reprod. 20, 1261–1265 (2005).

  135. 135.

    , , , & Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. Hum. Reprod. 14, 354–358 (1999).

  136. 136.

    et al. The chromosomal normality of unfertilized oocytes from patients with polycystic ovarian syndrome. Hum. Reprod. 12, 474–477 (1997).

  137. 137.

    et al. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. J. Clin. Endocrinol. Metab. 85, 995–1000 (2000).

  138. 138.

    et al. Oocyte quality in polycystic ovaries revisited: identification of a particular subgroup of women. J. Assist. Reprod. Genet. 14, 254–261 (1997).

  139. 139.

    , , , & Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment. J. Clin. Endocrinol. Metab. 92, 1430–1433 (2007).

  140. 140.

    et al. Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization. J. Clin. Endocrinol. Metab. 91, 2327–2333 (2006).

  141. 141.

    et al. Insulin and messenger ribonucleic acid expression of insulin receptor isoforms in ovarian follicles from nonhirsute ovulatory women and polycystic ovary syndrome patients. J. Clin. Endocrinol. Metab. 89, 3561–3566 (2004).

  142. 142.

    , , & Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. J. Clin. Endocrinol. Metab. 92, 705–713 (2007).

  143. 143.

    , , & Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin. Endocrinol. (Oxf.) 57, 343–350 (2002).

  144. 144.

    , , , & South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts. Eur. J. Obstet. Gynecol. Reprod. Biol. 134, 202–207 (2007).

  145. 145.

    , & Polycystic ovary syndrome and oocyte developmental competence. Obstet. Gynecol. Surv. 63, 39–48 (2008).

  146. 146.

    et al. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum. Reprod. 17, 2573–2579 (2002).

  147. 147.

    et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum. Reprod. Update 12, 673–683 (2006).

  148. 148.

    , , , & Obstetric outcome in women with polycystic ovarian syndrome. Hum. Reprod. 16, 226–229 (2001).

  149. 149.

    et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum. Reprod. 20, 2122–2126 (2005).

  150. 150.

    , , & Pregnancy in infertile PCOD patients. Complications and outcome. J. Reprod. Med. 42, 501–505 (1997).

  151. 151.

    et al. Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome. Gynecol. Endocrinol. 19, 134–140 (2004).

  152. 152.

    et al. Low birth weight and later development of insulin resistance and biochemical/clinical features of polycystic ovary syndrome. Metabolism 57, 999–1004 (2008).

  153. 153.

    et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int. J. Obes. Relat. Metab. Disord. 27, 710–715 (2003).

  154. 154.

    et al. Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives. J. Clin. Endocrinol. Metab. 95, 789–799 (2010).

  155. 155.

    et al. Birth weight and age at menarche in patients with polycystic ovary syndrome or diminished ovarian reserve, in a retrospective cohort. Hum. Reprod. 18, 2225–2230 (2003).

  156. 156.

    et al. High prevalence of polycystic ovary syndrome in women born small for gestational age. Hum. Reprod. 25, 2124–2131 (2010).

  157. 157.

    Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: are the molecular mechanisms distinct from type 2 diabetes? Panminerva Med. 50, 279–294 (2008).

  158. 158.

    , , & Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38, 1165–1174 (1989).

  159. 159.

    & Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil. Steril. 82, 661–665 (2004).

  160. 160.

    , , , & Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22, 141–146 (1999).

  161. 161.

    et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22, 920–924 (1999).

  162. 162.

    et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87, 1017–1023 (2002).

  163. 163.

    , , , & Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr. Diab. Rep. 6, 77–83 (2006).

  164. 164.

    , , & Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J. Clin. Endocrinol. Metab. 90, 3236–3242 (2005).

  165. 165.

    , , , & Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum. Reprod. 16, 1995–1998 (2001).

  166. 166.

    , , & Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16, 347–363 (2010).

  167. 167.

    et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum. Reprod. 15, 785–789 (2000).

  168. 168.

    , & Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med. 111, 607–613 (2001).

  169. 169.

    et al. Oxidised low-density lipoprotein concentration—early marker of an altered lipid metabolism in young women with PCOS. Eur. J. Endocrinol. 155, 131–136 (2006).

  170. 170.

    et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J. Clin. Endocrinol. Metab. 93, 1276–1284 (2008).

  171. 171.

    et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89, 5454–5461 (2004).

  172. 172.

    , & Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome. J. Endocrinol. Invest. 31, 35–41 (2008).

  173. 173.

    & Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J. Atheroscler. Thromb. 12, 237–239 (2005).

  174. 174.

    Long-term health consequences of PCOS. Hum. Reprod. Update 8, 231–241 (2002).

  175. 175.

    , , & Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome. J. Endocrinol. Invest. doi:10.3275/7294.

  176. 176.

    et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case–control study. J. Clin. Endocrinol. Metab. 93, 470–476 (2008).

  177. 177.

    , , , & Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J. Clin. Endocrinol. Metab. 78, 1052–1058 (1994).

  178. 178.

    , , & Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 1929–1935 (2005).

  179. 179.

    et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet. Gynecol. 106, 131–137 (2005).

  180. 180.

    et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 48–53 (2006).

  181. 181.

    et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum. Reprod. 23, 153–159 (2008).

  182. 182.

    , , & Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metab. 86, 4666–4673 (2001).

  183. 183.

    et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am. J. Med. 119, 356.e1–356.e6 (2006).

  184. 184.

    et al. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am. J. Obstet. Gynecol. 174, 1224–1229 (1996).

  185. 185.

    , , & Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum. Reprod. 22, 3197–3203 (2007).

  186. 186.

    et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler. Thromb. Vasc. Biol. 20, 2414–2421 (2000).

  187. 187.

    et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88, 2562–2568 (2003).

  188. 188.

    , & Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann. Intern. Med. 126, 32–35 (1997).

  189. 189.

    et al. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil. Steril. 54, 255–259 (1990).

  190. 190.

    et al. Menstrual cycle irregularity as a marker of cardiovascular risk factors at postmenopausal years. Arq. Bras. Endocrinol. Metabol. 50, 876–883 (2006).

  191. 191.

    , & Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 14, 284–292 (2007).

  192. 192.

    , , , & Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil. Steril. 87, 1369–1376 (2007).

  193. 193.

    , , & Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil. Steril. 91, 207–212 (2009).

  194. 194.

    et al. Factors associated with risk for depression among women with polycystic ovarian syndrome. Fertil. Steril. 90 (Suppl.), S178 (2008).

  195. 195.

    , , , & Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J. Clin. Epidemiol. 57, 1279–1287 (2004).

  196. 196.

    et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 49, 1255–1260 (2000).

  197. 197.

    et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J. Affect. Disord. 74, 299–304 (2003).

  198. 198.

    et al. Insulin resistance and depressive symptoms in young adult males: findings from Finnish military conscripts. Psychosom. Med. 69, 723–728 (2007).

  199. 199.

    et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav. Immun. 22, 177–184 (2008).

  200. 200.

    , & Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71, 171–186 (2009).

  201. 201.

    , & Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom. Med. 66, 356–362 (2004).

  202. 202.

    , , , & Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N. Engl. J. Med. 329, 1383–1388 (1993).

  203. 203.

    & Screening for bipolar disorder in women with polycystic ovary syndrome: a pilot study. J. Affect. Disord. 91, 205–209 (2006).

  204. 204.

    et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol. Psychiatry 59, 1078–1086 (2006).

  205. 205.

    et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord. 7, 246–259 (2005).

  206. 206.

    et al. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J. Affect. Disord. 89, 217–225 (2005).

  207. 207.

    , , & Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod. Biomed. Online 19, 398–405 (2009).

  208. 208.

    , , , & Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol. Endocrinol. 20, 200–208 (2005).

  209. 209.

    , & Polycystic ovary syndrome and endometrial cancer. Semin. Reprod. Med. 26, 62–71 (2008).

  210. 210.

    et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 25, 544–551 (2010).

  211. 211.

    et al. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol. Obstet. Invest. 69, 274–280 (2010).

  212. 212.

    , & Polycystic ovary syndrome: an ancient disorder? Fertil. Steril. doi:10.1016/j.fertnstert.2010.09.032.

  213. 213.

    , , , & Correlates of increased lean muscle mass in women with polycystic ovary syndrome. Eur. J. Endocrinol. 161, 583–589 (2009).

  214. 214.

    , , , & Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil. Steril. 72, 21–25 (1999).

  215. 215.

    & Eating, exercise, and “thrifty” genotypes: connecting the dots toward an evolutionary understanding of modern chronic diseases. J. Appl. Physiol. 96, 3–10 (2004).

  216. 216.

    , & Type 2 diabetes, cardiovascular disease, and the evolutionary paradox of the polycystic ovary syndrome: a fertility first hypothesis. Am. J. Hum. Biol. 21, 587–598 (2009).

  217. 217.

    The evaluation and management of hirsutism. Obstet. Gynecol. 101, 995–1007 (2003).

  218. 218.

    , , , & Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertil. Steril. 70, 274–278 (1998).

  219. 219.

    et al. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil. Steril. 72, 915–925 (1999).

  220. 220.

    et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1105–1120 (2008).

  221. 221.

    , , & Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur. J. Endocrinol. 162, 193–212 (2010).

  222. 222.

    et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411–418 (2010).

  223. 223.

    et al. Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. J. Clin. Endocrinol. Metab. 92, 4546–4556 (2007).

  224. 224.

    et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95, 2038–2049 (2010).

  225. 225.

    Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective. Fertil. Steril. 90, 14–16 (2008).

  226. 226.

    & Review: aromatase inhibitors for ovulation induction. J. Clin. Endocrinol. Metab. 91, 760–771 (2006).

  227. 227.

    , , & Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30, 1–50 (2009).

  228. 228.

    , & Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. Fertil. Steril. 92, 849–852 (2009).

Download references

Author information

Affiliations

  1. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA

    • Mark O. Goodarzi
  2.  Division of Reproductive Endocrinology and Infertility, Department of Obstetrics & Gynecology, The David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA

    • Daniel A. Dumesic
    •  & Gregorio Chazenbalk
  3.  Department of Obstetrics & Gynecology, Cedars-Sinai Medical Center, 8635 West Third Street, Los Angeles, CA 90048, USA

    • Ricardo Azziz

Authors

  1. Search for Mark O. Goodarzi in:

  2. Search for Daniel A. Dumesic in:

  3. Search for Gregorio Chazenbalk in:

  4. Search for Ricardo Azziz in:

Contributions

All authors contributed to researching data for the article, a substantial contribution to the discussion of content, writing, and reviewing/editing the manuscript before submission.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Ricardo Azziz.

Supplementary information

Powerpoint files

  1. 1.

    Supplementary Figure 1

    Evaluation of patients with potential hyperandrogenism

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrendo.2010.217

Further reading